Current Good Manufacturing Practice; Proposed Amendment of Certain Requirements for Finished Pharmaceuticals
Reinstatement with change of a previously approved collection
No
Regular
Approved without change
06/21/1999
04/22/1999
table that charts list comparision
Inventory as of this Action
Requested
Previously Approved
08/31/2002
08/31/2002
4,184
0
0
848,625
0
0
0
0
0
Section 501(a)(2)(B)(21 U.S.C. 351(a)(2)(B)) of the Food, Drug, and Cosmetic Act deems a drug to be adulterated if the methods used in, or controls used for, its manufacture, processing, packing, or holding do not conform to or are not operated or administered in conformity with current good manufacturing practices. The CGMP regulations implement that statutory mandate. The agency uses these records to determine whether the methods, facilities, and controls used in manufacturing, processing, packing, and holding of drugs conform to good manufacturing practices. FDA has determine that these....
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.